C. Daniel Mullins, PhD

C. Daniel Mullins, PhD Professor, Pharmacoeconomics Chair, Dept. of Pharmaceutical Health Services Research University of Maryland, College of Pharmacy BS, Economics, M.I.T. MA, Economics, Duke University PhD, Economics, DukeUniversity

Dr. Mullins's research and teaching focuses on Pharmacoeconomics, Pharmaceutical/health outcomes research, pharmaceutical pricing, and economic analysis of the pharmaceutical industry. Teaching responsibilities include a PhD/PharmD course on Pharmaceutical Economics and a PharmD course on Context of Health Care and lectures in various other classes.

SELECTED PUBLICATIONS:

• Mullins CD, Wang J, Cooke JL, Blatt L, Baquet CR. Longitudinal versus Cross-Sectional Methodology for Estimating the Economic Burden of Breast Cancer: A Pilot Study. Pharmacoeconomics 2003 (forthcoming).
• Cohen LA, Manski RJ, Magder LS, Mullins CD. Use of Physicians' Offices by a Medicaid Population for Dental Emergencies. American Journal of Public Health 2003 (forthcoming).
• Pradel FG, Mullins CD, Bartlett ST. Exploring Donors and Recipients Attitudes About Living Donor Kidney Transplant. Progress in Transplantation 2003 (forthcoming).
• Mullins CD, Thomas SK, Pradel FG, Bartlett ST. The Economic Impact of Laparoscopic Living-donor Nephrectomy on Kidney Transplantation. Transplantation 2003; 75(9):1505-12.
• Pradel FG, Limcangco MR, Mullins CD, Bartlett ST. Patients' Attitudes About Living Donor Transplantation and Living Donor Nephrectomy. American Journal of Kidney Diseases 2003 41(4):849-58.
• Mullins CD, Ndiritu EM, Yoder DM, Shaya FT, Taylor TA. Impact of the Fourth Hurdle on the International Pharmaceutical Industry. Expert Review of Pharmacoeconomics & Outcomes Research 2003; 3(2):169-177.
• Mullins CD, Ohsfeldt RL. Modeling the Annual Costs of Postmenopausal Prevention Therapy: Raloxifene, Alendronate, or Estrogen-Progestin Therapy. Journal of Managed Care Pharmacy 2003; 9(2):150-8.
• Merchant S, Mullins CD, Shih YT. Factors Associated with Hospitalization Costs for Patients with Community-Acquired Pneumonia Clinical Therapeutics 2003; 25(2):593-610.
• Palumbo FB, Mullins CD. The Development of Direct-to-Consumer Prescription Drug Advertising Regulation. Food and Drug Law Journal 2002; 57(3):423-43.
• Thomas SK, Brooks SE, Mullins CD, Baquet CR, Merchant S. Use of ICD-9 Coding as a Proxy for Stage of Disease in Lung Cancer. Pharmacoepidemiology and Drug Safety 2002; 11(8):709-13.
• Brooks SE, Ahn J, Mullins CD, Baquet CR. Resources and Use of the Intensive Care Unit in Patients Who Undergo Surgery for Ovarian Carcinoma. Cancer 2002; 95(7):1457-62.
• Shaya FT, Mullins CD, Wong W. Incidence versus prevalence modeling in pharmacoeconomics. Expert Review of Pharmacoeconomics & Outcomes Research 2002; 2(5):435-42.
• Shaya FT, Mullins CD, Wong W, Cho J. Discontinuation Rates of Topical Glaucoma Medications in a Managed Care Population. The American Journal of Managed Care 2002 8(10 suppl):S271-7.
• Mullins CD, Philbeck TE, Schroeder WJ, Thomas SK. Cost Effectiveness of Kinetic Therapy in Preventing Nosocomial Lower Respiratory Tract Infections in Patients Suffering from Trauma. Managed Care Interface 2002; 15(8):35-40.
• Mullins CD, Blak BT, Akhras KS. Comparing Cost-Effectiveness Analyses of Anti-Hypertensive Drug Therapy for Decision Making: Mission Impossible? Value in Health 2002; 5(4):359-71.
• Cohen LA, Manski RJ, Magder LS, Mullins CD. Dental visits to hospital emergency departments by adults receiving Medicaid: Assessing their use. Journal of the American Dental Association 2002; 133:715-24.
• Baquet CR, Hammond C, Commiskey P, Brooks S, Mullins CD. Health Disparities Research - A Model for Conducting Research on Cancer Disparities: Characterization and Reduction. Journal of the Association for Academic Minority Physicians 2002; 13(2):33-40.
• Mullins CD, Blatt L, Wang J. Societal implications of the pharmacoeconomics of Alpha 1-antitrypsin deficiency. Expert Review of Pharmacoeconomics & Outcomes Research 2002; 2(3):243-9.
• Brooks SE, Mullins CD, Guo C, Chen TT, Gardner JF, Baquet CR. Resource Utilization for Patients Undergoing Hysterectomy with or without Lymph Node Dissection for Endometrial Cancer. Gynecologic Oncology 2002; 85(2):242-9.

CONSULTING/ADVISORY BOARD:

• AstraZeneca
• Aventis
• Aventis Behring
• Bayer Pharmaceutical Division
• BlueCross/Blue Shield Association
• Bristol-Meyers Squibb
• Eli Lilly
• GlaxoSmithKline
• Merck
• Pfizer Pharmaceuticals
• Pharmacia Corporation